GUIDANCE DOCUMENT
CVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs March 2023
Not for implementation. Contains non-binding recommendations.
This guidance is being distributed for comment purposes only.
Submit Comments by
Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the FDA considers your comment on a draft guidance before it begins work on the final version of the guidance, submit either online or written comments on the draft guidance before the close date.
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2023-D-0606
- Docket Number:
- FDA-2023-D-0606
- Issued by:
-
Guidance Issuing OfficeCenter for Veterinary Medicine
The effectiveness development plan for topical otic products should be designed to show that the drug product is effective for its intended use (i.e., to treat otitis externa) and, if it is a combination product, each active ingredient makes a contribution to the effectiveness of the combination.
Target animal safety (TAS) studies aim to identify the margin of safety and provide veterinarians with information regarding the safe use of the drug. This guidance includes recommendations specific for topical otic drug products. Human user safety covers human exposures resulting from actual conditions of use and is part of the TAS technical section. Human user safety concerns for topical otic drug products should be addressed, including potential exposure to the drug and the active metabolites by veterinary personnel, people handling the drug, and people in contact with the animal.
The pathogenic species listed on the package insert will be determined by the results of the field effectiveness study that support substantial evidence of effectiveness.
Questions?
- Lea Cranford
- Center for Veterinary Medicine
Food and Drug Administration
7500 Standish Place, HFV-118
Rockville, MD 20855
- lea.cranford@fda.hhs.gov
- 240-402-0615